`
`Filed: March 8, 2019
`
`
`____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________
`
`MYLAN PHARMACEUTICALS INC.
`
`Petitioner
`
`v.
`
`HORIZON PHARMA USA, INC. and NUVO PHARMACEUTICALS
`(IRELAND) DESIGNATED ACTIVITY COMPANY,
`Patent Owners
`____________________________
`
`Case No. IPR2018-00272
`U.S. Patent No. 9,393,208
`____________________________
`
`PETITIONER’S OBJECTIONS TO PATENT OWNERS’ EVIDENCE
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.64(b)(1), Petitioner Mylan Pharmaceuticals Inc.
`
`(“Petitioner”) objects to the admissibility of the following exhibits filed by Patent
`
`Owners Horizon Pharma USA, Inc. and Nuvo Pharmaceuticals (Ireland) Designated
`
`Activity Company (“Patent Owners”) in the Patent Owners’ Response in the above-
`
`captioned inter partes review.
`
`Petitioner’s objections are timely under 37 C.F.R. § 42.64(b)(1) because they
`
`are being filed and served within five business days. Petitioner’s objections provide
`
`notice to Patent Owners that Petitioner may move to exclude these exhibits under 37
`
`C.F.R. § 42.64(c).
`
`In this paper, a reference to “FRE” means the Federal Rules of Evidence, a
`
`reference to “CFR” means the Code of Federal Regulations, and “’208 patent”
`
`means U.S. Patent No. 9,393,208. All objections under FRE 801-803 (hearsay)
`
`apply to the extent Patent Owners rely on the exhibits identified in connection with
`
`that objection for the truth of the matter asserted therein.
`
`Exhibit descriptions provided in this table are taken from Patent Owners’
`
`exhibit list and are used for identification purposes only. The use of the description
`
`does not indicate that Petitioner agrees with the descriptions or characterizations of
`
`the documents.
`
`
`
`- 1 -
`
`
`
`Exhibit
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007-
`2011
`2012
`
`2013
`
`Description
`Gabriel, S.E., et al., “Risk for Serious
`Gastrointestinal Complications Related to Use of
`Nonsteroidal Anti-inflammatory Drugs,” Annals of
`Internal Medicine, Vol. 115, No. 10, pp. 787-796
`(1991) (“Gabriel”)
`Cryer, B. and Feldman, M., “Effects of
`Nonsteroidal Anti-inflammatory Drugs on
`Endogenous Gastrointestinal Prostaglandins and
`Therapeutic Strategies for Prevention and
`Treatment of Nonsteroidal Anti-inflammatory
`Drug-Induced Damage,” Archives of Internal
`Medicine, Vol. 152, pp. 1145-1155 (1992)
`(“Cryer”)
`Fries, J.F., et al., “Nonsteroidal Anti-Inflammatory
`Drug-Associated Gastropathy: Incidence and Risk
`Factor Models,” The American Journal of
`Medicine, Vol. 91, pp. 213-222 (1991) (“Fries”)
`U.S. Patent No. 9,220,698 Prosecution History
`Excerpt: Response to Final Office Action Mailed
`March 26, 2015 (Sept. 25, 2015)
`U.S. Patent No. 9,220,698 Prosecution History
`Excerpt: Advisory Action (Oct. 9, 2015)
`Pozen Inc. Bankruptcy Petition dated August 10,
`2018
`Exhibits Not Used
`
`Gabriel, S.E., et al., Risk for Serious
`Gastrointestinal Complications Related to Use of
`Nonsteroidal Anti-inflammatory Drugs, Annals of
`Internal Medicine, Vol. 115, No. 10, pp. 787-796
`(1991) (with publication information)
`Cryer, B. and Feldman, M., Effects of Nonsteroidal
`Anti-inflammatory Drugs on Endogenous
`Gastrointestinal Prostaglandins and Therapeutic
`Strategies for Prevention and Treatment of
`Nonsteroidal Anti-inflammatory Drug-Induced
`Damage, Archives of Internal Medicine, Vol. 152,
`pp. 1145-1155 (1992) (with publication
`information)
`
`Objection
`A, B, D, F, G,
`H, M, N, O
`
`A, B, D, F, G,
`H, M, N, O
`
`A, B, D, F, G,
`H, M, N, O
`
`A, I, M, N, O
`
`A, I, M, N, O
`
`A, C, E, I, M,
`N, O
`P
`
`A, D, F, G, H,
`M, N, O
`
`A, D, F, G, H,
`M, N, O
`
`
`
`- 2 -
`
`
`
`Exhibit
`2014
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`2020
`
`2021
`
`2022
`
`Description
`Fries, J.F., et al., Nonsteroidal Anti-Inflammatory
`Drug-Associated Gastropathy: Incidence and Risk
`Factor Models, The American Journal of
`Medicine, Vol. 91, pp. 213-222 (1991) (with
`publication information)
`Jan. 12, 2017 Trial Testimony of John R.
`Plachetka in the Horizon Pharma, Inc. v. Dr.
`Reddy’s Laboratories, Inc., Case No. 3:11-cv-
`02317 (D.N.J.)
`Jan. 24, 2018 Deposition Testimony of Dr. John R.
`Plachetka in the Horizon Pharma, Inc. v. Dr.
`Reddy’s Laboratories, Inc., Case No. 3:15-cv-
`03324 (D.N.J.)
`PROTECTIVE ORDER MATERIAL
`PN400-104 Clinical Study Report
`PROTECTIVE ORDER MATERIAL
`Oct. 12, 2017 Deposition Testimony of Everardus
`Orlemans, Ph.D. in the Horizon Pharma, Inc. v. Dr.
`Reddy’s Laboratories, Inc., Case No. 3:15-cv-
`03324 (D.N.J.)
`Oct. 27, 2017 Deposition Testimony of Mark
`Sostek, MD in the Horizon Pharma, Inc. v. Dr.
`Reddy’s Laboratories, Inc., Case No. 3:15-cv-
`03324 (D.N.J.)
`PROTECTIVE ORDER MATERIAL
`Oct. 25, 2017 Deposition Testimony of Brian Ault,
`Ph.D. in the Horizon Pharma, Inc. v. Dr. Reddy’s
`Laboratories, Inc., Case No. 3:15-cv-03324
`(D.N.J.)
`PROTECTIVE ORDER MATERIAL
`Norman, A. and Hawkey, C.J., What you need to
`know when you prescribe a proton pump inhibitor,
`Frontline Gastroenterology, Vol. 2, pp. 199-205
`(2011)
`Stollman, N. and Metz, D.C., Pathophysiology and
`prophylaxis of stress ulcer in intensive care unit
`patients, J. Critical Care, Vol. 20, pp. 35-45 (2005)
`
`Objection
`A, D, F, G, H,
`M, N, O
`
`A, B, C, D, E,
`F, G, H, I, J,
`M, N, O, W
`
`A, B, C, D, E,
`F, G, H, I, J,
`M, N, O, W
`
`A, B, C, D, E,
`F, I, M, N, O
`A, B, C, D, E,
`F, G, H, I, J,
`M, N, O, W
`
`A, B, C, D, E,
`F, G, H, I, J,
`M, N, O, W
`
`A, B, C, D, E,
`F, G, H, I, J,
`M, N, O, W
`
`A, C, D, E, F,
`G, H, M, N, O
`
`A, D, F, G, H,
`M, N, O
`
`
`
`- 3 -
`
`
`
`Exhibit
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`2028
`
`2029
`
`2030
`
`2031
`
`2032
`
`Description
`Declaration of Michael Mayersohn, Ph.D. in
`Support of Defendants’ Claim Construction Brief
`filed on April 24, 2014 in Par Pharm., Inc. v.
`Takeda Pharm. Co., Case No. 5:13-CV-1927 LHK
`(PSG)
`January 30, 2013 Amendment C and Response to
`Final Office Action, Application No. 12/553,107
`Declaration of David R. Taft PH.D. In Support of
`Patent Owner Response to Petition for Inter Partes
`Review of U.S. Patent No. 9,393,208
`Declaration of David A. Johnson. M.D. In Support
`of Patent Owner Response to Petition for Inter
`Partes Review of U.S. Patent No. 9,393,208
`IPR2017-01995, May 25, 2018 Deposition
`Transcript of David C. Metz
`
`Redacted Amended Memorandum Opinion (D.I.
`498), Case 3:11-cv-02317-MLC-DEA (D.N.J. July
`12, 2017)
`IPR2017-01995, May 24, 2018 Deposition
`Transcript of Dr. Michael Mayersohn
`
`Oct. 16, 2014 Deposition Testimony of Brian Ault,
`Ph.D. in the Horizon Pharma, Inc. v. Dr. Reddy’s
`Laboratories, Inc., Case No. 3:11-cv-02317
`(D.N.J.)
`PROTECTIVE ORDER MATERIAL
`Oct. 10, 2014 Deposition Testimony of Dr. Mark
`Sostek in the Horizon Pharma, Inc. v. Dr. Reddy’s
`Laboratories, Inc., Case No. 3:11-cv-02317
`(D.N.J.)
`PROTECTIVE ORDER MATERIAL
`Email string from Tore Lind to Richard Leff,
`Doug Levine, David Magner, and Mark Sostek,
`dated May 27, 2006 to May 31, 2006
`
`Objection
`A, B, C, D, E,
`F, G, H, I, M,
`N, O
`
`A, I, M, N, O
`
`A, D, F, G, H,
`I, N, O, Q, S,
`T, U
`A, D, F, G, H,
`I, N, O, Q, S,
`T, U
`A, B, D, F, G,
`H, I, K, L, M,
`N, O, Q, S, T,
`U
`A, C, E, I, M,
`N, O
`
`A, B, D, F, G,
`H, I, K, L, M,
`N, O, Q, S, T,
`U
`A, B, C, D, E,
`F, G, H, I, J,
`M, N, O, W
`
`A, B, C, D, E,
`F, G, H, I, J,
`M, N, O, W
`
`A, B, D, F, I,
`J, K, M, N, O,
`R
`
`
`
`- 4 -
`
`
`
`Exhibit
`2033
`
`2034
`
`2035
`
`2036
`
`2037
`
`2038
`
`2039
`
`2040
`
`2041
`
`2042
`
`2043
`
`Description
`Andersson et al., Pharmacokinetic Studies with
`Esomeprazole, the (S)-Isomer of Omeprazole,
`CLIN. PHARMACOKINET., 40(6):411-426 (2001)
`Tolman et al., The Effects of Oral Doses of
`Lansoprazole and Omeprazole on Gastric pH, J.
`CLIN. GASTROENTEROL., 24(2):65-70 (1997)
`Hartmann et al., Twenty-four-hour intragastric pH
`profiles and pharmacokinetics following single
`and repeated oral administration of the proton
`pump inhibitor pantoprazole in comparison to
`omeprazole, ALIMENT PHARMACOL. THER.,
`10:359-366 (1996)
`Leucuta et al., Pharmcokinetics and Metabolic
`Drug Interactions, CURRENT CLINICAL
`PHARMACOLOGY, 1:5-20 (2006)
`Meyer, Interaction of Proton Pump Inhibitors with
`Cytochromes P450: Consequences for Drug
`Interactions, YALE J. BIOL. MED., 69:203-209
`(1996)
`Prilosec Label
`
`Vanderhoff et al., Proton Pump Inhibitors: An
`Update, AMERICAN FAMILY PHYSICIAN, 66:273-
`280 (2002)
`Arnold, Safety of proton pump inhibitors-an
`overview, Aliment Pharmacol. Ther., 8 (Suppl.
`1):65-70 (1994)
`VIMOVO Prescribing Information
`
`M.M. Wolfe et al., Gastrointestinal toxicity of
`nonsteroidal antiinflammatory drugs, N. Engl. J.
`Med., 340(24):1888-1899 (1999)
`L. Laine, Nonsteroidal anti-inflammatory drug
`gastropathy, Gastrointest. Endosc. Clin. North
`Am., 6(3):489–504 (1996)
`
`Objection
`A, D, F, G, H,
`M, N, O
`
`A, D, F, G, H,
`M, N, O
`
`A, D, F, G, H,
`M, N, O
`
`A, D, F, G, H,
`M, N, O
`
`A, D, F, G, H,
`M, N, O
`
`A, B, C, E, M,
`N, O
`A, D, F, G, H,
`M, N, O
`
`A, D, F, G, H,
`M, N, O
`
`A, B, C, D, E,
`F, H, M, N, O
`A, D, F, G, M,
`N, O
`
`A, D, F, G, M,
`N, O
`
`
`
`- 5 -
`
`
`
`Exhibit
`2044
`
`2045
`
`2046
`
`2047
`
`2048
`
`2049
`
`2050
`2051
`
`2052
`
`Description
`F.E. Silverstein et al., Gastrointestinal toxicity
`with celecoxib vs. nonsteroidal anti-inflammatory
`drugs for osteoarthritis and rheumatoid arthritis:
`the CLASS study: A randomized controlled trial,
`JAMA, 284(10):1247–1255 (2000)
`C. Bombardier et al., Comparison of upper
`gastrointestinal toxicity of rofecoxib and naproxen
`in patients with rheumatoid arthritis, N. Engl. J.
`Med., 343(21):1520–1528 (2000)
`G. Singh, Gastrointestinal complications of
`prescription and over-the-counter nonsteroidal
`anti-inflammatory drugs: a view from the ARAMIS
`database, Am. J. Ther., 7:115–121 (2000)
`NIH, National Institute of Diabetes and Digestive
`and Kidney Diseases, Bleeding in the Digestive
`Tract, available at http://www.niddk.nih.gov/
`health-information/health-topics/digestive-
`diseases/bleeding-in-the-digestive-tract/
`Pages/facts.aspx (last accessed March 23, 2015)
`K.S. Jain, et al., Recent advances in proton pump
`inhibitors and management of acid-peptic
`disorders, Bioorganic & Medicinal Chemistry
`15:1181-1205 (2007)
`N. Hudson et al., Famotidine for healing and
`maintenance in nonsteroidal anti-inflammatory
`drug-associated gastroduodenal ulceration,
`Gastroenterology, 112:1817-1822 (1997)
`Exhibit Not Used
`L. Olbe et al., Reviews: A Proton-pump inhibitor
`expedition: The case histories of omeprazole and
`esomeprazole, Nature 2:132-139 (2003)
`C.W. Howden, Clinical pharmacology of
`omeprazole, Clin. Pharmacokinet 20(1):38-49
`(1991)).
`
`Objection
`A, D, F, G, M,
`N, O
`
`A, D, F, G, M,
`N, O
`
`A, D, F, G, M,
`N, O
`
`A, B, C, D, E,
`F, I, K, M, N,
`O
`
`A, D, F, G, M,
`N, O
`
`A, D, F, G, M,
`N, O
`
`P
`A, D, F, G, M,
`N, O
`
`A, D, F, G, M,
`N, O
`
`
`
`- 6 -
`
`
`
`Exhibit
`2053
`
`2054
`
`2055
`
`2056
`
`2057
`
`2058
`
`2059
`
`2060
`
`2061
`
`2062
`
`Description
`J.Q. Huang & R.H. Hunt, Pharmacological and
`pharmacodynamic essentials of H2-receptor
`antagonists and proton pump inhibitors for the
`practising physician, Best Prac. & Res. Clin.
`Gastroenterol. 15(3):355-370 (2001)
`H. Koop, Review article: metabolic consequences
`of long-term inhibition of acid secretion by
`omeprazole, Aliment. Pharmacol. Ther. 6:399–406
`(1992)
`Donnellan C., Preston C., Moayyedi P., Sharma
`N., Medical treatments for the maintenance
`therapy of reflux oesophagitis and endoscopic
`negative reflux disease (Review), The Cochrane
`Library, Issue 4, at 14 (2004)
`D.A. Johnson, Review of esomeprazole in the
`treatment of acid disorders, Expert Opin.
`Pharmacother. 4(2):253-264 (2003)
`Nexium label
`
`S.H. Roth, NSAID gastropathy: A new
`understanding, Arch. Intern. Med. 156:1623–1628
`(1996)
`W. Bensen & A. Zizzo, Newer, safer nonsteroidal
`anti-inflammatory drugs. Rational NSAID
`selection for arthritis, Can. Fam. Physician
`44:101-102, 105-107 (1998)
`R.J. Flower, Reviews: The development of COX2
`inhibitors, Nature 2:179-191 (2003)
`Wolfe et al., Gastroprotective therapy and risk of
`gastrointestinal ulcers: risk reduction by COX-2
`therapy, J. Rheumatol. 29(3):467-473 (2002)
`FDA Public Health Advisory, April 7, 2005,
`available at
`http://www.fda.gov/drugs/drugsafety/postmarketdrug
`safetyinformationforpatientsandproviders/ucm1503
`14.htm (last accessed March 23, 2015)).
`
`Objection
`A, D, F, G, M,
`N, O
`
`A, D, F, G, M,
`N, O
`
`A, B, C, D, E,
`F, G, M, N, O
`
`A, D, F, G, M,
`N, O
`
`A, B, C, D, E,
`F, M, N, O
`A, D, F, G, M,
`N, O
`
`A, D, F, G, M,
`N, O
`
`A, D, F, G, M,
`N, O
`A, D, F, G, M,
`N, O
`
`A, B, C, D, E,
`F, I, K, M, N,
`O
`
`
`
`- 7 -
`
`
`
`Exhibit
`2063
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`2069
`
`2070-
`2072
`2073
`
`Description
`J.L. Wallace et al., Gastrointestinal-sparing anti-
`inflammatory drugs: the development of nitric
`oxide-releasing NSAIDs, Drug Dev Res 42:144-
`149 (1997)
`F.L. Lanza, A guideline for the treatment and
`prevention of NSAID-induced Ulcers, Am. J.
`Gastroenterol., 93(11):2037–2046 (1998)
`J.L. Goldstein et al., Impact of adherence to
`concomitant gastroprotective therapy on
`nonsteroidal-related gastroduodenal ulcer
`complications, Clin. Gastroenterol. & Hepatology,
`4:1337-1345 (2006)
`J.L. Goldstein et al., Clinical trial: the incidence of
`NSAID-associated endoscopic gastric ulcers in
`patients treated with PN 400 (naproxen plus
`esomeprazole magnesium) vs. enteric-coated
`naproxen alone, Aliment Pharmacol. Ther.,
`32:401-413 (2010)
`AstraZeneca/Pozen Collaboration and License
`Agreement (August 1, 2006)
`PROTECTIVE ORDER MATERIAL
`Exhibit Not Used
`M. Hassan-Alin et al., Pharmacokinetics of
`esomeprazole after oral and intravenous
`administration of single and repeated doses to
`healthy subjects, Eur. J. Clin. Pharmacol., 56:665-
`670 (2000)
`Exhibits Not Used
`
`Opinion & Order, filed on November 14, 2017 in
`Horizon Pharma, Inc. v. Dr. Reddy’s
`Laboratories, Inc., Civ. A. No. 2:15-cv-03324-
`SRC-CLW (SRC)
`
`Objection
`A, D, F, G, M,
`N, O
`
`A, B, D, F, G,
`M, N, O
`
`A, D, F, G, M,
`N, O
`
`A, B, C, D, E,
`F, G, M, N, O
`
`A, B, C, D, E,
`F, I, K, M, N,
`O
`P
`A, B, D, F, G,
`M, N, O
`
`P
`
`A, C, E, I, M,
`N, O
`
`
`
`- 8 -
`
`
`
`Exhibit
`2074
`
`2075
`
`2076
`
`2077
`
`
`
`Description
`Memorandum of Mylan and DRL in Support of
`Their Motion for Summary Judgment of Invalidity
`of U.S. Patent Nos. 9,220,698 and 9,393,208, filed
`on November 12, 2018 in Horizon Pharma, Inc. v.
`Dr. Reddy’s Laboratories, Inc., Civ. A. No. 2:15-
`cv-03324-SRC-CLW (SRC)
`Opinion, filed on November 19, 2018 in Horizon
`Pharma, Inc. v. Dr. Reddy’s Laboratories, Inc.,
`Civ. A. No. 2:15-cv-03324-SRC-CLW (SRC)
`Final Judgment Under Rule 54(b), signed and filed
`January 22, 2019 in Horizon Pharma, Inc. v. Dr.
`Reddy’s Laboratories, Inc., Civ. A. No. 2:15-cv-
`03324-SRC-CLW (SRC)
`Final Judgment Under Rule 54(b), signed and filed
`January 22, 2019 in Horizon Pharma, Inc. v. Dr.
`Reddy’s Laboratories, Inc., Civ. A. No. 2:15-cv-
`03324-SRC-CLW (SRC)
`
`Objection
`A, C, E, I, M,
`N, O
`
`A, C, E, I, M,
`N, O
`
`A, C, E, I, M,
`N, O
`
`A, C, E, I, M,
`N, O
`
`Petitioner objects to paragraphs in the Patent Owners’ Response that rely on
`
`exhibits objected to in this Petitioner’s Objections to Patent Owners’ Evidence.
`
`
`
`- 9 -
`
`
`
`Objection Key:
`
`A:
`B:
`C:
`
`D:
`
`E:
`
`F:
`
`G:
`
`H:
`
`I:
`
`J:
`
`K:
`L:
`M:
`N:
`
`O:
`
`P:
`Q:
`
`
`
`FRE 801/802/803 (hearsay)
`FRE 901/902 (lacking authentication)
`FRE 402 (relevance) the document is not relevant to any issue in this IPR
`proceeding because the purported date of the document is after the filing
`date of the ’208 patent or the prior art status is not clear
`FRE 402 (relevance) to the extent the document is relied upon for secondary
`considerations of nonobviousness, there is no nexus to the claimed
`compositions and methods
`FRE 403 (confusing, waste of time) the document is not relevant to any
`issue in this IPR proceeding because the purported date of the document is
`after the filing date of the ’208 patent or the prior art status is not clear
`FRE 403 (confusing, waste of time) to the extent the document is relied
`upon for secondary considerations of nonobviousness, there is no nexus to
`the claimed compositions and methods
`FRE 702 (improper expert testimony) expert testimony that relies on the
`document is not based on sufficient facts or data and/or is not the product of
`reliable principles and methods
`FRE 703 (bases of expert opinion) expert testimony that relies on the
`document is unreliable because the document is not of a type reasonably
`relied upon by experts in the field
`FRE 106 (completeness) the document is incomplete and includes only a
`select portion of a larger document that in fairness should be considered
`along with this document
`FRE 701, 702 (improper expert testimony) improper expert testimony by a
`lay witness
`FRE 1001-1003 (best evidence)
`FRE 403, 901 (improper compilation)
`FRE 403 (cumulative)
`FRE 402 (relevance) the document is not relevant to any issue in the IPR
`proceeding
`FRE 403 (confusing, waste of time) the document is not relevant to any
`issue in the IPR proceeding
`No exhibit filed.
`Expert testimony fails to identify with particularity the underlying facts or
`data on which the opinion is based, violating 37 C.F.R. § 42.65(a)
`
`- 10 -
`
`
`
`FRE 602 (lack of personal knowledge)
`FRE 702/703 to the extent that the expert declarant relies on an exhibit
`objected to under grounds G and H, the testimony is (i) not based on
`sufficient facts or data and/or is not the product of reliable principles and
`methods and/or is (ii) is unreliable because the exhibit is not of a type
`reasonably relied upon by experts in the field
`FRE 1006 (improper summary)
`37 C.F.R. § 42.65 (fails to provide underlying facts or data on which opinion
`is based)
`Exhibit is improper new evidence untimely filed with a request for
`rehearing, in violation of 37 C.F.R. § 42.71
`Improper uncompelled direct testimony (not submitted as an affidavit),
`contrary to 37 C.F.R. § 42.53.
`
`R:
`S:
`
`T:
`U:
`
`V:
`
`W:
`
`
`
`Dated: March 8, 2019
`
`Respectfully submitted,
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`Reg. No. 52,354
`Perkins Coie LLP
`700 13th St., NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6206
`E-mail: bmwhite@perkinscoie.com
`
`
`
`- 11 -
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing PETITIONER’S
`
`OBJECTIONS TO PATENT OWNERS’ EVIDENCE was served electronically via
`
`email as follows:
`
`Thomas A. Blinka
`Jonathan G. Graves
`Ellen Scordino
`Cooley LLP
`zIPR2018-00272@cooley.com
`
`Margaret J. Sampson
`Stephen M. Hash
`Jeffrey S. Gritton
`Baker Botts LLP
`nuvo-vimovoBB@bakerbotts.com
`
`Dated: March 8, 2019
`
`
`
`
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`Reg. No. 52,354
`Attorneys for Petitioner Mylan Pharmaceuticals Inc.
`
`